{"id":742961,"date":"2023-03-28T01:03:08","date_gmt":"2023-03-28T05:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/"},"modified":"2023-03-28T01:03:08","modified_gmt":"2023-03-28T05:03:08","slug":"athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/","title":{"rendered":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference"},"content":{"rendered":"<h2>\nData highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF\/MET system<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BOTHELL, Wash., March  28, 2023  (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD\/PD\u2122 2023 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders (AD\/PD).<\/p>\n<p>\u201cNew therapeutic strategies for neurodegenerative diseases are urgently needed. Our presentations at AD\/PD highlight a wide range of preclinical evaluations demonstrating the ability of fosgonimeton, or its active metabolite fosgo-AM, acting through the HGF\/MET system, to address multiple aspects of neurodegeneration,\u201d said Kevin Church, Ph.D., Chief Scientific Officer of Athira.\u00a0\u201cThese findings include notable neuroprotective, neurotrophic, and anti-inflammatory effects, as well as reduction of disease-related protein pathologies following multiple and varied challenges in models of Alzheimer\u2019s and Parkinson\u2019s.\u201d<\/p>\n<p>Data presented in three poster presentations highlight the effects of fosgonimeton or fosgo-AM, acting through the HGF\/MET pathway, demonstrating:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Significant protection from neurite degeneration and cell death in cultures of primary cortical or dopaminergic neurons challenged with several neurological insults central to Alzheimer\u2019s and Parkinson\u2019s disease pathologies.<\/li>\n<li style=\"margin-bottom:8pt\">Protection from protein pathologies, including significantly reduced levels of hyperphosphorylated tau in cortical neurons treated with toxic amyloid beta, and significantly lower levels of \u03b1-synuclein aggregation in dopaminergic neurons treated with toxic insults.<\/li>\n<li style=\"margin-bottom:8pt\">Significant anti-inflammatory effects on immune cells <em>in vitro <\/em>and significant procognitive activity in a model of neuroinflammation-induced cognitive impairment <em>in vivo<\/em>.<\/li>\n<\/ul>\n<p>The presentations are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8McwAc2pLh8x4pnGooMBxme9XFv2QJNYvSDE5xfIFCrbVBhUEv193F6hu7PEPGxO2zr2Ut_czg8JL2ZrtKUUm4BVSWfn-uTC23aXBURutt_hibqxXamcqOWU-nFQG4QrJA-nOTiJp6XEthk8yE_QLNR2414O3cwRDJQVHUEIW6U=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Scientific Publications &amp; Presentations<\/u><\/a> page of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w54vCGueFQPj188ao25nhS9oRPuFnHvfun1aM4aDVmF9dweBe6x1rbg5Sjc9nkEwbVs0WW0WKJBzDxnsys9J6g==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.athira.com<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>About Athira Pharma, Inc.<\/strong>\u00a0<br \/>Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF\/MET neurotrophic system for Alzheimer\u2019s and Parkinson\u2019s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w54vCGueFQPj188ao25nhRXEdcQqRUw_pxfn06ZK2wAzl7Z6wkVcCsoomWLwmHicMEfXDa6ufx4tspeQsNEWgODDrSHayoHVChInTwXqEfghvukMCCjIUv1PNS_5fV8zEv2lmdJiys40jrSMNSx8-YPNZdOfTeYhMyn6QM6fNHdFTsyhdGjZ0N01nIe5XMKTrsCOoEVlfJTyvY7vgFtSE740LVzHI-MEpPLiJNHviVKFySri6Wn-Q89fOdoJJi7oxZrJaKqkG_c8hyCZV5AzLGvTSW3Dd3yphKORL7RzgISxDFuPZgB1K_0imaETtn_J8Li1RJR6_tIFObMi3sTEYefUo4ZGfLZbs3Q8Tf6TPC4UX2DVchTCwuKe9mj8b6EAKDDfMk2GVVjx-MP0EZKCCPfKWm9ddDaO5UgEQrCIzuy654XQ9lbLiYxn8o-92l9ARvcH0DxrYHYgYROkv0b1iF_cQcNUZ9uRKftS-or5KPMk6CepopvLRw0lFQj_uQzw_L40C4M4acjAdS8KNqGafugxlvc7oMxNnpIDmmr7pWO3_QimTjxk_wX2czdqvPwGq9lph0kflvpHk1GjeEaeLMNrZoymiktfRChI0GeyyUzDdhQ3a4n8PrI_C9dn2u2BpwxZNy5-SGAqzV4ZdctH1J7m3rIu0nZ724Dw6UPsR7c=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.athira.com<\/u><\/a>. You can also follow Athira on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QxMxW8gGinItfUS6mKmmBToiMlsuC7tHtjz9YTqEOLUgR1RxOW1uCsnrON76lJwFEZB2lRo3ehKmcjjiQs0VGtgmtY6-gQId-POWECYvf9hU5DIpfW95QHKzjFCh4vbcDxtNcuDZBYwef-JJatIi9RqntpueXxYLVXFAO0UdfUhHuJMGoqJLNKzlZRsFqv9AT5FqYQRa7kPggW4NOs19AG20_oXbLkQAOh7zaUVqmiKI-QA_S4th68O9tgBYDFLKSnH3r2GtVFO6e2jrm-wlHJCAztLaTGTP3dXNjc7f3TVE9uPslHBnjk2RxtMZweMnoZocK8043TaNsj4J_hgb1j_DFL2TKUoQ-7NdChpD13LCkaHsUT82Stbk_aMCR7SYJ-KElmtnsOScLL_Lbx91p1ikbiTDIhQJSANtV2CtzPye_Cas4xasawzgxQxtzt1ph7v8WI3QcXaxXVX_kzGqEh8gSxRRI8R5UNuQC09ovYjSprbTRCKb-Rv2wgazLILyGXsYUE2p3lX3LTrtNFYOG6LSiPFjd3WBVfIde9o8hDXLvznAkfdvgZ0ZxzCDof10sXx_G5jd_XLdRPnHOSyEhIOcB7TL0yn-chE18PRlLmQjqLl09N0kSFjk81HqO4foUQ8iEnBtQA_k1OKElGJkK6pUiP2vWxJZu6MS5ZEkc2rBMR5ylxPANMMZ4p9MMEx8\" rel=\"nofollow noopener\" target=\"_blank\"><u>Facebook<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ko_ibdcHQju30kRhoosc_5yKNtTwNHziSTtqEn62APxKkc6PDYs2mbbRdQljtDuW9XDXtQWgTXlt_yLD_WD8bL6ZBxfyMrs6RWJ27nC4EVYFwk6AMMKkUHdk75LOmIsbwdjPRsCCMRjpLeTihmpB68GVhAMEkNfLlC-Dwa0N586_TnIjxapjmrvY1FoVTsjLr-CS7Y__82ZdJFm-ZxCC3093mt9m_g7rh13N4VNZJQisQrTxQmaD2hUcNqRGRE1jxMtetkVL1RKes17CK2ZWsCgT2gUiEPfnBpfHbWPweCYQL-jHrgsFxIVtCEp5dRJVx-uGcg93SzmEEwBqi7HNfcbrMot7u5CRTn_XvlYOLh0lNFFOCK_kehIct1_aQS28UEJMtHbmjFyxWqu-tsGMXGLWZZwrhudaGpZdatV49OVGHSy-rLCLpBNxMpyYR3qfhyPeJeSVMVoX0MKc9d3K4-Tk36Vi0t4spnpxIzO-5mNj8VkT5DKxhXhiV6PmPJkON_gnsndpz7IMgMhPB4eExn0pvlVMj0nQYTUxRec5YQWUpeBESKuohYogQ37hQbqSyjsM_kyYDvBhEQV7FbYoBOJfPnPUG5PvvHifCiNz1jij21KlsKfljPIzaSI7XJKE5Tpe6TVOHX-dkKDP9cPCgdARo50Nunt7k7MDlnBXC3XbHQ7U9rInluQGL5Cuf77A\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a><u>, <\/u>and @athirapharma on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L1m9X7Qbpfl73qrMjCC0-tlnKU9BYfVISoa1hZ85B-vjcUV25JlaZsOLY_t6bGxhmQwehoNC4mvNPYlBiRuRAQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vxC3IGDiszkrSnLHTxctNa3nVtXlJek_S4jXSfDLU2U9a7Dioj-sJaMMPpZ_Q-JwxbU9_yFBJYkYHT_XlRnoRLm-9tXLFUO2rGsWRX73irr3aTxocDKsLsOxHk2Dpv7CQ3tlme1-knTbEggj2-Usq0DMRTRi0U40NIGjqt3U1Kfd2Ch2y2rQBf62ka9t7FdNMnAPAGkiBioDXy5H9CqMfFeYsqp5cPb2zuazH2JTnLG4LzzcTIQ8lYttCnxVS-exPTxyDtWRDScp9NSdgdctTzCfXWSMjUN_SGpXWTCc0N0CMuzKIIs70Q3PRqtw_-hz3o2OaFBfNcCAGWSQ8jzwEV8x3vRVM_F7RbelBB6ATUia-eZgLT0dx1_QuX0AHqzg5UiOxbAYzjd2P_5qIvEmHE9gMLmIV6Lz0693kPguH4d6xrhNYApYv8vrnFdEKO_v62jTm2Lvp8DUoqxavKIVXIRBoNcLHdRqMt9jje_k9c9jbmsgi3AO9UXeInwcazmFuSB4ZrYdO9weE7P6wj45tfB0n-EmCMtfIE2ObCdW5qu2YCkRICpw8TKqrdaw5TKdOP9O0E2FaUWzYggAsNzvSkdRR0ts7JDEvi28NLExDnxHhQXxkDWhG_qDkDiCHhqV-dZaUWYUghADtEia6QKTAEj7n63SNm1DEI6LF7AcNlm0r6pjjCdxmHzr6ihpwIPN\" rel=\"nofollow noopener\" target=\"_blank\"><u>Instagram<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\u00a0<\/p>\n<p>This communication contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer\u2019s disease, Parkinson\u2019s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis; Athira\u2019s platform technology and potential therapies; expectations regarding the potential efficacy and commercial potential of Athira\u2019s product candidates; and Athira\u2019s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201con track,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cintend,\u201d \u201cpursue,\u201d \u201ccontinue,\u201d \u201csuggest,\u201d \u201cpotential,\u201d and other similar expressions, among others. Any forward-looking statements are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data for our product candidates from our preclinical and clinical trials not supporting the safety, efficacy and tolerability of our product candidates; cessation or delay of Athira\u2019s development of product candidates may occur; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira\u2019s business, research and clinical development plans and timelines, and the regulatory process for Athira product candidates; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira\u2019s product candidates; possible negative interactions of Athira&#8217;s product candidates with other treatments; Athira\u2019s assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira\u2019s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira\u2019s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact<\/strong>\u00a0<br \/>Julie Rathbun\u00a0<br \/>Athira Pharma\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K13ZTnabAaSTWaxPdMsIV4LMp0JcS-0B_54f-AuUSUH3uNHTFhZaIY6UEDuoPjeEzulEoczSvWekOYeM0S7XHW88ZCjgfJwLe7d1EYl821D1Z9ktvtZXHS7NjdHId_3fwQWH75bUCkXkw1r_3qsDZy6FNssYyTGoGBllAgLJsjZatfm4m-WDR-v0tDdqkFznTjU7iOccBfZO9-cpKJ3ZBe5NoyfTm0cRIDqwQmdvAWczI0yLylLafe-SCEQ5kU4j9-yyozoYuq0ljTS9MWpuMw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Julie.rathbun@athira.com<\/u><\/a>\u00a0<br \/>206-769-9219<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWM5MzA5ZmQtMmE1Ny00OTMyLTg1M2UtMGYyMmUwNmI2YTBhLTEyMTM0NDQ=\/tiny\/Athira-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF\/MET system BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD\/PD\u2122 2023 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders (AD\/PD). \u201cNew therapeutic strategies for neurodegenerative diseases are urgently needed. Our presentations at AD\/PD highlight a wide range of preclinical evaluations demonstrating the ability of fosgonimeton, or its active metabolite fosgo-AM, acting through the HGF\/MET system, to address multiple aspects of neurodegeneration,\u201d said Kevin Church, Ph.D., Chief Scientific Officer of Athira.\u00a0\u201cThese &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF\/MET system BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD\/PD\u2122 2023 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders (AD\/PD). \u201cNew therapeutic strategies for neurodegenerative diseases are urgently needed. Our presentations at AD\/PD highlight a wide range of preclinical evaluations demonstrating the ability of fosgonimeton, or its active metabolite fosgo-AM, acting through the HGF\/MET system, to address multiple aspects of neurodegeneration,\u201d said Kevin Church, Ph.D., Chief Scientific Officer of Athira.\u00a0\u201cThese &hellip; Continue reading &quot;Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T05:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\\\/PD\u2122 2023 International Conference\",\"datePublished\":\"2023-03-28T05:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/\"},\"wordCount\":926,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/\",\"name\":\"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\\\/PD\u2122 2023 International Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\",\"datePublished\":\"2023-03-28T05:03:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\\\/PD\u2122 2023 International Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference - Market Newsdesk","og_description":"Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF\/MET system BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) &#8212; Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting the potential therapeutic benefits of fosgonimeton at the AD\/PD\u2122 2023 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and Related Neurological Disorders (AD\/PD). \u201cNew therapeutic strategies for neurodegenerative diseases are urgently needed. Our presentations at AD\/PD highlight a wide range of preclinical evaluations demonstrating the ability of fosgonimeton, or its active metabolite fosgo-AM, acting through the HGF\/MET system, to address multiple aspects of neurodegeneration,\u201d said Kevin Church, Ph.D., Chief Scientific Officer of Athira.\u00a0\u201cThese &hellip; Continue reading \"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T05:03:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference","datePublished":"2023-03-28T05:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/"},"wordCount":926,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/","name":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=","datePublished":"2023-03-28T05:03:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ0NiM1NDk0NTUyIzIyMDE4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athira-pharma-presents-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-for-alzheimers-and-parkinsons-diseases-at-ad-pd-2023-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer\u2019s and Parkinson\u2019s Diseases at AD\/PD\u2122 2023 International Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}